Highlights UCB

Equities

UCB

BE0003739530

Real-time Euronext Bruxelles Other stock markets 08:35:30 2024-04-30 am EDT			5-day change	1st Jan Change
124.3 ^EUR	+0.61%		+2.05%	+57.48%

Apr. 11	Berenberg Reiterates UCB's Purchase Rating, Raises PT	MT
Apr. 11	UCB : Berenberg, Buy, raises its price target	CF

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ex-dividend day for final dividend	Apr. 25	FA
UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx	Apr. 04	CI
UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies	Mar. 08	CI
UCB : UCB all set to reach new highs	Mar. 08
UCB Secures British Regulatory Nod for Generalized Myasthenia Gravis Treatment	Mar. 07	MT
Samsung Biologics Strikes $353 Million Deal with Belgium's UCB	Mar. 07	MT
Global markets live: Reckitt, Apple, Warner, Eli Llily, Intel...	Feb. 28
UCB : H2 beat; the prospects remain encouraging	Feb. 28
UCB SA Provides Earnings Guidance for the Year 2025	Feb. 28	CI
UCB SA Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
ZILBRYSQ® Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis in Adult Patients Who Are Anti-Acetylcholine Receptor Antibody Positive	Jan. 03	CI
Drugmakers set to raise U.S. prices on at least 500 drugs in January	Dec. 29	RE
UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society Annual Meeting	Dec. 02	CI
UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis	Nov. 14	CI
UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor	Nov. 11	CI
UCB Presents New Five-Year Data on Bimzelx® (Bimekizumab-Bkzx) in Ankylosing Spondylitis	Nov. 10	CI
UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio	Nov. 01	CI
UCB SA Announces Publication of NAYZILAM® Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function for People with Seizure Clusters	23-10-31	CI
UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis	23-10-18	CI
UCB Announces U.S. FDA approval of ZILBRYSQ® for the Treatment of Adults with Generalized Myasthenia Gravis	23-10-17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

UCB : UCB all set to reach new highs

March 08, 2024 at 11:10 am EST